000			02265 a2200661 4500
005			20250518014308.0
264		0	_c20190319
008			201903s 0 0 eng d
022			_a1096-1208
024	7		_a10.1016/j.micpath.2018.12.040 _2doi
040			_aNLM _beng _cNLM
100	1		_aBamorovat, Mehdi
245	0	0	_aA single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models. _h[electronic resource]
260			_bMicrobial pathogenesis _cMar 2019
300			_a162-170 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnimals
650	0	4	_aAntiprotozoal Agents _xpharmacology
650	0	4	_aCell Line _xdrug effects
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aChild
650	0	4	_aChronic Disease _xtherapy
650	0	4	_aDrug Combinations
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInterleukin-10 _xmetabolism
650	0	4	_aInterleukin-12 Subunit p40 _xmetabolism
650	0	4	_aLeishmania tropica _xdrug effects
650	0	4	_aLeishmaniasis, Cutaneous _xdrug therapy
650	0	4	_aLevamisole _xadministration & dosage
650	0	4	_aMacrophages _xdrug effects
650	0	4	_aMale
650	0	4	_aMeglumine Antimoniate _xadministration & dosage
650	0	4	_aMice
650	0	4	_aMiddle Aged
650	0	4	_aNitric Oxide Synthase Type II _xmetabolism
650	0	4	_aTransforming Growth Factor beta _xmetabolism
650	0	4	_aTreatment Outcome
650	0	4	_aTumor Necrosis Factor-alpha _xmetabolism
650	0	4	_aYoung Adult
700	1		_aSharifi, Iraj
700	1		_aFekri, Alireza
700	1		_aKeyhani, Alireza
700	1		_aAflatoonian, Mohammad Reza
700	1		_aHeshmatkhah, Amireh
700	1		_aOliaee, Razieh Tavakoli
700	1		_aKhosravi, Ahmad
700	1		_aNaderi, Afsaneh
700	1		_aParizi, Maryam Hakimi
700	1		_aMostafavi, Mahshid
700	1		_aVarma, Rajender S
773	0		_tMicrobial pathogenesis _gvol. 128 _gp. 162-170
856	4	0	_uhttps://doi.org/10.1016/j.micpath.2018.12.040 _zAvailable from publisher's website
999			_c29195398 _d29195398